That the trial results were positive for CF? Given there are not many options for drug resistant pseudomonas, and most CF patients are on long courses of tobi or colistin or amikacin (poor absorption/penetration compared to arikace), they need another option for inhaled antibiotic therapy. It won't be first line, but you won't keep giving tobi or colistin to a patient whose pseudomonas has become resistant to those drugs. Arikace would be a better option than systemic antibiotics, which are reserved for active infections or patients with really poor lung function that can't tolerate another infection (pre-transplant). Some of you really are like the world is ending (longs I'm talking about, not even shorts). Sheesh
"It won't be first line, but you won't keep giving tobi or colistin to a patient whose pseudomonas has become resistant to those drugs."
I believe we've now got to the bit where you explain why Arikace will not be first line.
As a doctor and a scientist I know it's second nature for you to avoid speculation - and to only present as fact information you know to be indisputable.
My assumption that Arikace will be the central therapy in the antibiotic regimen by virtue of the fact that no other inhaled antibiotic has generated data which even hints at improving lung function for longer than a couple of phases of therapy is clearly flawed. I look forward to a clear explanation of the factor I've overlooked.